Literature DB >> 1661709

Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids.

N Ahmadzadeh1, M Shingu, M Nobunaga, T Tawara.   

Abstract

Leukotriene B4 (LTB4) was measured in synovial fluid from 20 patients with rheumatoid arthritis and 15 patients with osteoarthritis. The level of LTB4 was significantly higher in synovial fluid from rheumatoid arthritis patients as compared with synovial fluid from osteoarthritis patients. LTB4 levels also significantly correlated with cell numbers, rheumatoid factor, and immune complexes in synovial fluid from rheumatoid arthritis patients. There was an inverse correlation between LTB4 levels and complement components. The high-pressure liquid chromatography peak of immunoreactivity extracted from the synovial fluid occurred at a retention volume identical to that of authentic LTB4. These results suggest that the increased level of this mediator in synovial fluid may contribute to perpetuation of inflammation and tissue destruction in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661709     DOI: 10.1007/bf00923346

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  19 in total

1.  Precise standardization of reagents for complement fixation.

Authors:  J F KENT; E H FIFE
Journal:  Am J Trop Med Hyg       Date:  1963-01       Impact factor: 2.345

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  Comparison of the generation in vitro of chemotactically active LTB4 and its omega-metabolites by human neutrophils and lymphocytes/monocytes.

Authors:  T Rosenbach; B M Czarnetzki
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

Review 4.  The synovial lining cell: biology and pathobiology.

Authors:  B Henderson; E R Pettipher
Journal:  Semin Arthritis Rheum       Date:  1985-08       Impact factor: 5.532

5.  Rheumatoid arthritis: rheumatoid factors, immune complexes, and C-reactive protein are raised shortly after the onset of symptoms.

Authors:  V E Jones; R K Jacoby
Journal:  Arthritis Rheum       Date:  1989-01

6.  Leukotriene B4 in synovial fluid.

Authors:  E M Davidson; S A Rae; M J Smith
Journal:  J Pharm Pharmacol       Date:  1982-06       Impact factor: 3.765

7.  The stimulation of lysosomal enzyme secretion from human polymorphonuclear leucocytes by leukotriene B4.

Authors:  S A Rae; M J Smith
Journal:  J Pharm Pharmacol       Date:  1981-09       Impact factor: 3.765

8.  Leukotriene B4: an inflammatory mediator in vivo.

Authors:  M A Bray; A W Ford-Hutchinson; M J Smith
Journal:  Prostaglandins       Date:  1981-08

9.  Activation of neutrophils and the lesions of rheumatoid arthritis.

Authors:  G Weissmann
Journal:  J Lab Clin Med       Date:  1982-09

10.  The release of leukotriene B4 during experimental inflammation.

Authors:  P M Simmons; J A Salmon; S Moncada
Journal:  Biochem Pharmacol       Date:  1983-04-15       Impact factor: 5.858

View more
  18 in total

1.  A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

Authors:  M W Konstan; G Döring; S L Heltshe; L C Lands; K A Hilliard; P Koker; S Bhattacharya; A Staab; A Hamilton
Journal:  J Cyst Fibros       Date:  2014-01-17       Impact factor: 5.482

Review 2.  Too much of a good thing: How modulating LTB4 actions restore host defense in homeostasis or disease.

Authors:  Stephanie L Brandt; C Henrique Serezani
Journal:  Semin Immunol       Date:  2017-10       Impact factor: 11.130

3.  A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss.

Authors:  Hisako Hikiji; Satoshi Ishii; Takehiko Yokomizo; Tsuyoshi Takato; Takao Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-24       Impact factor: 11.205

4.  Leukotriene B4-induced granulocyte trafficking in guinea pig dermis. Effect of second-generation leukotriene B4 receptor antagonists, SC-50605 and SC-51146.

Authors:  D J Fretland; D L Widomski; C P Anglin; T D Penning; S Yu; S W Djuric
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

5.  The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats.

Authors:  Joice Maria Cunha; Daniela Sachs; Cláudio Azevedo Canetti; Stephen Poole; Sérgio Henrique Ferreira; Fernando Queiroz Cunha
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 6.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

7.  Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.

Authors:  D J Fretland; C P Anglin; M Bremer; P Isakson; D L Widomski; S K Paulson; S H Docter; S W Djuric; T D Penning; S Yu
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

Review 8.  Is Synovial Macrophage Activation the Inflammatory Link Between Obesity and Osteoarthritis?

Authors:  Antonia RuJia Sun; Thor Friis; Sunderajhan Sekar; Ross Crawford; Yin Xiao; Indira Prasadam
Journal:  Curr Rheumatol Rep       Date:  2016-09       Impact factor: 4.592

9.  Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling.

Authors:  Christian D Sadik; Nancy D Kim; Yoichiro Iwakura; Andrew D Luster
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

10.  Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids.

Authors:  Karina Roxana Gheorghe; Marina Korotkova; Anca Irinel Catrina; Linda Backman; Erik af Klint; Hans-Erik Claesson; Olof Rådmark; Per-Johan Jakobsson
Journal:  Arthritis Res Ther       Date:  2009-06-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.